Woolworths Group Selects One Door to Improve the Store Team Experience
One Door, Inc., the leading provider of cloud-based visual merchandising software, today announced a new multi-year agreement with the Woolworths Group. Woolworths will implement One Door’s Merchandising Cloud platform across its supermarkets to simplify and streamline work for its in-store merchandising teams.
“We are thrilled to partner with Woolworths to have a positive impact on the lives of their customers and team,” said Tom Erskine, CEO of One Door.
“Woolworths is a proven retail innovator and we both believe we are only just beginning to jointly understand how these technologies can ultimately improve the work experience for store teams and improve the overall customer experience.”
“We’re pleased to partner with One Door to roll out Merchandising Cloud for the benefit of our teams and customers,” said Doug Frank, Woolworths General Manager Group Data & Analytics.
“One Door allows us to simplify a critical and time intensive task - making life easier for in-store merchandisers and helping ensure our products are presented to customers the right way.
“As we continue to tailor and localise our range in different stores, it’s important we draw on the best technology to make it simpler for our stores to execute for our customers.
Merchandising Cloud is built for store teams first, transforming the way retailers plan, execute, and analyze their in-store merchandising. Merchandising Cloud is the only platform that converts existing, legacy planograms and floorplans into a mobile-first, interactive experience that guides store teams through tasks step-by-step, and shows them not just what to do, but how to do it.
Once work is complete, Merchandising Cloud uses AI-based Computer Vision and analytics to streamline real-time audits and provide insight into merchandising compliance and performance in every store. The result is more efficiency in stores, and a higher quality store experience.
About One Door
One Door, Inc. is the leading provider of cloud-based visual merchandising software. With One Door, space planners, visual merchandisers and store operations teams work across silos to plan, execute and analyze store merchandising plans in a unified, cloud-based platform. The result is higher sales, more store team efficiency, and better customer experiences. Learn more at https://onedoor.com/execution-compliance/
About Woolworths Group
Woolworths Group is a fresh food, drinks and everyday needs retailer united by a shared purpose of creating better experiences together for a better tomorrow. With more than 3,000 stores across its Woolworths Supermarkets, Countdown Supermarkets (New Zealand), BIG W, Dan Murphy’s and BWS brands, Woolworths Group is Australia and New Zealand’s largest retailer. A top 20 company on the Australian Securities Exchange (ASX), Woolworths Group employs more than 215,000 team members and serves more than 29 million customers every week. In FY20, Woolworths Group reported sales of $63.6bn (AUD), including $3.5bn in online sales.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Media Contact | One Door
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion Confirms Neutralising Potency Against Emerging SARS-CoV-2 Variants With Anti-COVID-19 Monoclonal Antibody Treatment regdanvimab (CT-P59)18.5.2021 09:39:00 EEST | Press release
Celltrion Group today announced that CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, has confirmed neutralising potency against emerging variants first identified in New York (B.1.526), Nigeria (B.1.525) and India (B.1.617).1 The Korea Disease Control and Prevention Agency (KDCA) has assessed the test by combining the antibody with recent emerging variants first identified in New York (B.1.526), Nigeria (B.1.525) and Brazil (P.1); infecting the host cell with this combination to identify neutralising effect against the variants with CT-P59. The monoclonal antibody candidate CT-P59 demonstrated strong neutralising capability against the New York (B.1.526) and Nigeria (B.1.525) variants and produced neutralising titers against the Indian variant (B.1.617) in an in-vitro pseudo virus assay.1 The company plans to study neutralising titers against additional emerging strains, including the Brazil variant (P.1)2, in order to proactively address the pandemic as the virus con
iBASIS Carrier Voice for Teamwork™ Enables China Telecom Europe (CTE) and the Carrier Community to Meet Surging Post-Pandemic Enterprise Demand18.5.2021 08:00:00 EEST | Press release
iBASIS, the leading provider of communications solutions for operators and digital players worldwide, today announced the launch of iBASIS Carrier Voice for Teamwork, enabling carriers such as China Telecom Europe (CTE), a leading provider to European multinationals, to serve Enterprise customers with much needed cloud-based PBX functionality for their collaboration platforms. With the massive shift toward Microsoft Teams triggered by COVID-19, carriers have an immediate opportunity to seize new Enterprise revenues by delivering a proven solution to bring voice to Microsoft Teams. iBASIS Carrier Voice for Teamwork™ provides global service availability, from and to the cloud via 2-way PSTN numbers, enabling native voice service in 60+ markets for global termination to help carriers respond to their local Enterprise demand. Carriers have the option to keep their own numbers to avoid porting or leverage iBASIS for local numbers. The solution is built on iBASIS’ established wholesale leade
Medicago and GSK Announce Positive Interim Phase 2 Results for Adjuvanted COVID-19 Vaccine Candidate18.5.2021 08:00:00 EEST | Press release
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) are pleased to report positive interim Phase 2 clinical trial safety and immunogenicity data for Medicago’s plant-derived COVID-19 vaccine candidate, which has been tested in combination with GSK’s pandemic adjuvant. These results are part of the ongoing Phase 2/3 study and reiterate the promising profile observed during Phase 1 testing. Immunogenicity, as measured by the neutralizing antibody titer, was high - about 10 times higher than those in a panel of sera from patients recovering from COVID-19. No related severe adverse events were reported and reactogenicity was generally mild to moderate and short in duration. “We are very excited to see such positive results from the Phase 2 data. After two doses, the adjuvanted vaccine candidate induced robust neutralizing antibody and cellular immune responses in all subjects, irrespectively of age,” said Nathalie Landry, Executive Vice President,
Stephen Stonberg appointed interim CEO of Bittrex Global17.5.2021 20:14:00 EEST | Press release
The Boards of Directors (the “Boards”) of Bittrex Global GmbH (Vaduz, Liechtenstein) and Bittrex Global (Bermuda) Ltd (Hamilton, Bermuda) have confirmed that Tom Albright is stepping down from his role as CEO of both companies effective today. The Boards are grateful for the contributions Tom has made. Stephen Stonberg, current CFO and COO of Bittrex Global, has been appointed by the Boards to serve as interim CEO, to oversee management of the Companies. “Tom has brought key leadership as Bittrex Global has grown to serve the crypto marketplace,” said Bill Shihara, Co-Founder Bittrex, Inc. “Tom has also helped guide the company through a period of significant growth and change within our sector”. “We are incredibly pleased that Stephen Stonberg will be leading Bittrex Global as interim CEO,” said Shihara. “Stephen has served as CFO and COO since February 2019, and has a deep understanding of our business, and has over 25 years experience in the financial services sector, and held leade
Lumen Metabolic Health Device Now Peer-reviewed17.5.2021 19:57:00 EEST | Press release
Lumen , a health tech company and the creators of the world's first portable metabolism measurement device, has officially been peer-reviewed and published in the Interactive Journal of Medical Research (I-JMR). In collaboration with San Francisco State University, Lumen has validated an ongoing study launched in 2020, which shows the validity of Lumen® to detect changes in metabolic fuel utilization in a comparable manner with a laboratory standard metabolic cart, providing the ability for real-time metabolic information for users under any circumstances. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210517005774/en/ Lumen now peer-reviewed (Photo: Business Wire) Developed through years of scientific testing and validation, Lumen is the first handheld, portable device and app that measures your metabolism in real-time with just your breath. The methodology behind the peer-reviewed validation of Lumen The study compares the
Orbia Announces Cash Tender Offer for Its Outstanding Notes Due 202217.5.2021 16:46:00 EEST | Press release
Orbia Advance Corporation, S.A.B. de C.V. (“Orbia”) (BMV: ORBIA) announces that it has commenced an offer to purchase its outstanding US$750,000,000 principal amount of 4.875% Senior Notes due 2022 (CUSIP/ISIN: 59284BAB4; P57908AD0 / US59284BAB45; USP57908AD01) (the “Securities”) pursuant to an offer (the “Tender Offer”) to purchase for cash any and all of the Securities on the terms and subject to the conditions set forth in the offer to purchase, dated May 17, 2021 (the “Offer to Purchase”) and the related notice of guaranteed delivery (the “Notice of Guaranteed Delivery” and, together with the Offer to Purchase, the “Offer Documents”). The Tender Offer will expire at 5:00 p.m. (New York City time) on May 21, 2021, unless extended (such date and time, as the same may be extended, the “Expiration Date”). Securities validly tendered may be withdrawn at any time at or prior to 5:00 p.m. (New York City time) on May 21, 2021, unless extended, but not thereafter. The settlement date of the
monday.com Announces Filing of Registration Statement for Proposed Initial Public Offering17.5.2021 15:45:00 EEST | Press release
monday.com Ltd. (“monday.com”), a work operating system (Work OS) where organizations of any size can create the tools and processes they need to manage every aspect of their work, announced today it has filed a registration statement on Form F-1 with the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. monday.com intends to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “MNDY.” Goldman Sachs & Co. LLC and J.P. Morgan will act as lead book-running managers for the proposed offering, with Allen & Company LLC and Jefferies acting as joint book-running managers. William Blair, Piper Sandler, Oppenheimer & Co., Canaccord Genuity, Cowen and Needham & Company will act as co-managers for the proposed offering. The offering will be made only by means of a prospectus. Copies of t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom